25 related articles for article (PubMed ID: 7903529)
1. Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition.
Yu L; Wang YF; Xiao J; Shen QQ; Chi SS; Gao YL; Lin DZ; Ding J; Fang YF; Chen Y
Acta Pharmacol Sin; 2023 Oct; 44(10):2113-2124. PubMed ID: 37225847
[TBL] [Abstract][Full Text] [Related]
2. The effect of iron on the expression levels of calcium related gene in cisplatin resistant epithelial ovarian cancer cells.
Kucukkaya B; Erdag D; Akbas F; Yalcintepe L
Explor Target Antitumor Ther; 2021; 2(4):309-322. PubMed ID: 36046755
[TBL] [Abstract][Full Text] [Related]
3. Lipid metabolism in ferroptosis and ferroptosis-based cancer therapy.
Sun Y; Xue Z; Huang T; Che X; Wu G
Front Oncol; 2022; 12():941618. PubMed ID: 35978815
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis in Cancer Treatment: Another Way to Rome.
Wu Y; Yu C; Luo M; Cen C; Qiu J; Zhang S; Hu K
Front Oncol; 2020; 10():571127. PubMed ID: 33102227
[TBL] [Abstract][Full Text] [Related]
5. The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer?
Zhou Y; Shen Y; Chen C; Sui X; Yang J; Wang L; Zhou J
Cancer Biol Med; 2019 Nov; 16(4):630-646. PubMed ID: 31908884
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-dependent disruption of intracellular iron metabolism augments the cytotoxic effects of doxorubicin in select breast and ovarian cancer cells.
Bajbouj K; Shafarin J; Hamad M
Cancer Manag Res; 2019; 11():4655-4668. PubMed ID: 31213891
[No Abstract] [Full Text] [Related]
7. Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells.
Arora HC; Jensen MP; Yuan Y; Wu A; Vogt S; Paunesku T; Woloschak GE
Cancer Res; 2012 Feb; 72(3):769-78. PubMed ID: 22158944
[TBL] [Abstract][Full Text] [Related]
8. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles.
Dufes C; Muller JM; Couet W; Olivier JC; Uchegbu IF; Schätzlein AG
Pharm Res; 2004 Jan; 21(1):101-7. PubMed ID: 14984263
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric evaluation of transferrin receptor in transitional cell carcinoma.
Rahman SA; Yokoyama M; Nishio S; Takeuchi M
Urol Res; 1997; 25(5):325-9. PubMed ID: 9373912
[TBL] [Abstract][Full Text] [Related]
10. A rapid redistribution of transferrin receptors to the cell surface of L2C lymphocytes upon fixation of holoform transferrin.
Sainte-Marie J; Vidal M; Philippot JR; Bienvenüe A
Biochem Mol Biol Int; 1995 Aug; 36(6):1161-8. PubMed ID: 8535287
[TBL] [Abstract][Full Text] [Related]
11. Structure of transferrin and transferrin receptor.
Kohgo Y
Nihon Ketsueki Gakkai Zasshi; 1986 Dec; 49(8):1627-34. PubMed ID: 3551439
[No Abstract] [Full Text] [Related]
12. Transferrin receptors associate with drug resistance in cancer cells.
Barabas K; Faulk WP
Biochem Biophys Res Commun; 1993 Dec; 197(2):702-8. PubMed ID: 7903529
[TBL] [Abstract][Full Text] [Related]
13. Detection of P-glycoprotein in solid tumors by flow cytometry.
Fujii H; Tanigawa N; Muraoka R; Shimomatsuya T; Tanaka T
Anticancer Res; 1993; 13(6A):2171-5. PubMed ID: 7905253
[TBL] [Abstract][Full Text] [Related]
14. Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells.
Berczi A; Barabas K; Sizensky JA; Faulk WP
Arch Biochem Biophys; 1993 Jan; 300(1):356-63. PubMed ID: 8424669
[TBL] [Abstract][Full Text] [Related]
15. Scanning electron microscopy of multidrug resistant cells in haematological and mammary malignancies.
Galimberti S; Bianchi F; Bernardini N; Mattii L; Dolfi A; Lupetti M; Petrini M
Cell Mol Biol (Noisy-le-grand); 1993 Jul; 39(5):543-51. PubMed ID: 8104068
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
